Suffering from prostate cancer or benign prostatic hyperplasia (BPH) is not the end of a relationship. Technology and ...
Data from a late-stage trial, presented on Sunday, indicate that the treatment, administered six months before and after surgery, substantially increased the chances of eliminating cancer and reduced ...
Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and death in late-stage studies. Read more at straitstimes.com. Read more at ...
Prostate cancer is the second leading cancer in men. Earlier this year, I got the disturbing diagnosis that I had stage three ...
FATHER’S Day is naturally all about the dads, but as well as celebrating the men in our lives, spare a thought for their ...
By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the ...
His advocacy has since expanded beyond the clinic through speaking engagements, media appearances and partnerships with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results